| Patient | Sonny Liston |
|---|---|
| Date of birth | 1989-05-08 |
| Identifiers | MRN HR-BX007-SYN; SSN (made up) 000-07-8853 |
| Document date | 2026-07-21 |
| Author | Malcolm Achebe-Whitford, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week review of blood pressure and drinking. [S]
Sonny Liston returns four weeks after starting amlodipine 5 mg and valsartan 160 mg. He has taken it every morning and can say what it is for and when to take it. He did not send home readings for the first two weeks: the clinic had asked him to photograph the monitor and send the picture, and the steps on the phone were confusing. After a nurse called him in the third week he began reading the numbers out on the clinic voice line; the last seven mornings average 134/84 mmHg. No dizziness or ankle swelling. Drinking is down to about 15 drinks a week, but he still has five or six on Saturday nights and finds he cannot stop once he starts; he asks for the medicine he was told about. No thoughts of suicide. [S]
| Element | Detail |
|---|---|
| Home readings | Average 134/84 mmHg over the last seven mornings |
| Potassium and creatinine | 4.4 mmol/L and 1.1 mg/dL |
| AUDIT-C | 7 |
| Teach-back | Correct with the picture card |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Neurological | Negative | No dizziness or headaches |
| Gastrointestinal | Negative | No abdominal pain, nausea or yellowing |
| Psychiatric | Negative | Mood all right; no thoughts of suicide |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg and valsartan 160 mg combined oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-06-23 to 2026-07-21 | completed | S |
| Amlodipine 10 mg and valsartan 160 mg combined oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-07-21 | active | S |
| Naltrexone 50 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-07-21 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-21 | Body height | 185 | cm | S |
| 2026-07-21 | Body weight | 98 | kg | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 28.6 | kg/m2 | S |
| 2026-07-21 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-07-21 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-07-21 | Heart rate | 58 | /min | S |
| 2026-07-21 | Respiratory rate | 14 | /min | S |
| 2026-07-21 | Body temperature | 36.6 | Cel | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-21 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-21 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-21 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 89 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-21 | Total score [AUDIT-C] | 7 | {score} | S |
Vital signs recorded on 2026-07-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 136/86 mmHg (average of two); pulse 58; weight 98.0 kg |
| Cardiovascular | Regular rhythm; no edema |
| Abdomen | Liver not enlarged; no tenderness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| High blood pressure readings at a first visit (154/98 mmHg, average of two readings with a large cuff), without a diagnosis of hypertension; out-of-office confirmation needed | resolved | confirmed | R03.0 | S — Synthetic presenting finding; resolved into the diagnosis at the consultation visit when ambulatory monitoring confirmed hypertension. |
| Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (daytime average 146/94 mmHg, nighttime 132/84 mmHg), with mild concentric left ventricular hypertrophy on echocardiography and normal kidney function and urine albumin | active | confirmed | I10 | S — Synthetic modern diagnosis; no hypertension is documented in his life. |
| Alcohol use disorder, moderate (four DSM-5-TR criteria: drinking more than intended, unsuccessful efforts to cut down, craving, and continued drinking despite its effect on his training, blood pressure and liver tests); AUDIT 16 | active | confirmed | F10.20 | S — Synthetic modern diagnosis by interview, anchored to the description of heavy drinking; not a historical diagnosis. |
| Personal history of physical abuse in childhood (beaten regularly by his father), with heavy field work from the age of eight | active | confirmed | Z62.810 | S — Synthetic coding of the documented childhood history; physical abuse only. |
| Does not read or write (no schooling as a child); prefers spoken explanations, pictures and demonstrations | active | confirmed | Z55.0 | S — Synthetic coding of the documented literacy, recorded so that care is adapted. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, large cuff, average of two readings), weight and BMI, heart sounds | Every visit | Completed today | 136/86 mmHg; weight 98.0 kg |
| Examination | Out-of-office blood pressure (ambulatory or home monitoring) | At diagnosis and after each treatment change | Deferred | Deviation: home readings were asked for each morning from the start of treatment but none arrived for two weeks, because the photo-upload steps were not usable for him and teach-back had not covered them. Office and later home readings agree, so no harm is known. Corrective action: readings by voice message, shown with teach-back by the nurse; seven readings in the last week averaged 134/84 mmHg |
| Laboratory | Potassium, creatinine and eGFR | Baseline; two to four weeks after starting an ARB; then every six months on an ARB | Completed today | Potassium 4.4 mmol/L, creatinine 1.1 mg/dL, eGFR 89, four weeks after starting valsartan; next in about six months |
| Laboratory | Lipids, glucose or A1c, urine albumin-to-creatinine ratio, TSH | At diagnosis, then yearly (TSH at diagnosis) | Up to date | Done at intake; next yearly |
| Imaging | Echocardiogram | At diagnosis for stage 2 hypertension or suspected LVH; repeat as indicated | Up to date | Mild LVH at two weeks; repeat in about a year to look for regression with control |
| Medication safety | Antihypertensive tolerance (ankle edema, dizziness) and adherence by teach-back | Each follow-up and each dose change | Completed today | No dizziness or edema on 5/160 mg; teach-back correct; dose raised today with a new picture card |
| Referral | Fitness to compete (AHA/ACC athlete statement) | At diagnosis and before returning to competition | Up to date | Not yet controlled; no bouts |
| Survey | Drinking (AUDIT-C, drinks per week, drinking days) | Every follow-up during treatment; full AUDIT at about four months | Completed today | AUDIT-C 7; about 15 drinks a week, with heavy Saturday nights |
| Laboratory | Liver tests (AST, ALT, GGT) | Baseline; about two months after starting naltrexone or cutting down; then as indicated | Ordered | Intake AST 46, ALT 38, GGT 88 U/L; recheck in about two months on naltrexone |
| Medication safety | Naltrexone: nausea, liver tests, and opioid-blockade wallet card | Each follow-up after starting | Completed today | Started today; no opioid use; wallet card given |
| Survey | Suicide-risk review (structured questions) and safety plan | Every visit | Completed today | No thoughts of suicide |
| Self-management | Health literacy: teach-back, picture card, read-aloud consent, voice reminders | Every visit | Completed today | Teach-back of the new dose and of naltrexone correct; voice-message readings set up |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension and depression monographs (2026); The Healthcare Professional's Core Resource on Alcohol (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition (2024)
Follow-up: Preventive visit in three weeks. Three-month review in two months with liver tests and AUDIT-C. Call 988 or the clinic at any time if thoughts of suicide arise. Next scheduled visit 2026-08-11: periodic adult preventive visit. [S]